Dogs are resistant to prion infection, due to the presence of aspartic or glutamic acid at position 163 of their prion protein

Enric Vidal | Natalia Fernández-Borges | Hasier Eraña | Beatriz Parra
Belen Pintado | Manuel A. Sánchez-Martín | Jorge M. Charco
Montserrat Ordóñez | Miguel A. Pérez-Castro | Martí Pumarola
Candace K. Mathiason | Tomás Mayoral | Joaquín Castilla

1IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, Barcelona, Spain
2CIC bioGUNE, Derio, Spain
3Laboratorio Central de Veterinaria (LCV), Madrid, Spain
4Centro Nacional de Biotecnología (CNB), Madrid, Spain
5Servicio de Transgénesis, Nucleus, Universidad de Salamanca, Salamanca, Spain
6IBSAL, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
7Departament de Medicina i Cirurgia Animals. Facultat de Veterinària, UAB, Barcelona, Spain
8Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
9IKERBASQUE, Basque Foundation for Science, Bilbao, Spain

Correspondence
Joaquín Castilla, CIC bioGUNE, Parque tecnológico de Bizkaia, Derio 48160, Bizkaia, Spain.
Email: castilla@joaquin castilla.com

Abstract
Unlike other species, prion disease has never been described in dogs even though they were similarly exposed to the bovine spongiform encephalopathy (BSE) agent. This resistance prompted a thorough analysis of the canine PRNP gene and the presence of a negatively charged amino acid residue in position 163 was readily identified as potentially fundamental as it differed from all known susceptible species. In the present study, the first transgenic mouse model expressing dog prion protein (PrP) was generated and challenged intracerebrally with a panel of prion isolates, none of which could infect them. The brains of these mice were subjected to in vitro prion amplification and failed to find even minimal amounts of misfolded prions providing definitive experimental evidence that dogs are resistant to prion disease. Subsequently, a second transgenic model was generated in which aspartic acid in position 163 was substituted for asparagine (the most common in prion susceptible species) resulting in susceptibility to BSE-derived isolates. These findings strongly support the hypothesis that the amino acid residue at position 163 of canine cellular prion protein (PrPc) is a major determinant of the exceptional resistance of the canidae family to prion infection and establish this as a promising therapeutic target for prion diseases.

KEYWORDS
canids, canine, dog, interspecies transmission, prion infection, prion susceptibility, scrapie, transgenic mouse models, transmission barrier, transmissible spongiform encephalopathy

Abbreviations: BSE, bovine spongiform encephalopathy; BSE-C, classical BSE strain; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease of cervids; FSE, feline spongiform encephalopathy; IHC, immunohistochemistry; L-BSE, atypical low-BSE strain, low electrophoretic pattern; MAb, monoclonal antibody; NAPA, nonadaptive prion amplification; NBH, normal, non-infected brain homogenate; PBS, phosphate buffered saline; PCR, polymerase chain reaction; PrP, prion protein; PrPc, cellular prion protein; PrPSc, misfolded protease-resistant pathological prion protein; PRNP, gene encoding the cellular prion protein; PMCA, protein misfolding cyclic amplification; SSBP1, classical scrapie isolate, sheep scrapie brain pool 1; TSE, transmissible spongiform encephalopathy; vCJD, variant Creutzfeldt-Jakob disease; WB, Western blot.

Enric Vidal and Natalia Fernández-Borges have contributed equally to this work.

[Correction added on January 29, 2020, after initial online publication: Article title has been modified and missing funding sources added in the acknowledgment section.]
1 | INTRODUCTION

Prion diseases are a group of invariably fatal neurodegenerative disorders for which no effective treatment or prophylaxis exist currently. Many mammalian species are susceptible and all share a common pathogenesis: the misfolding of the host-encoded cellular prion protein (PrP<sup>C</sup>) into a pathological con-former misfolded protease-resistant pathological prion protein (PrP<sup>res</sup>) that accumulates in the brain leading to neurodegeneration and death. Research efforts have been directed primarily at human prionopathies and those of domestic animals of commercial interest. However, other species have been of interest either as a disease model or due to their lack of susceptibility to infection. The study of species with significantly different prion susceptibilities is key to understanding the biological mechanisms underlying these diseases.

The PrP<sup>C</sup> misfolding event can be sporadic (putatively spontaneous), caused by mutations in the PRNP gene or triggered by externally acquired infectious prions. Currently, the “mad cow disease” epizootic is under control but other animal prion diseases, such as scrapie in small ruminants or chronic wasting disease (CWD) in cervids, are endemic in many countries and the recent spread of CWD to the European continent is of great concern. Interspecies transmission of prions is a well-established phenomenon and bovine spongiform encephalopathy (BSE) is one of the best examples. Exposure of various species to feedstuff contaminated with BSE prions caused several diseases including variant Creutzfeldt-Jakob disease (vCJD) in humans, feline spongiform encephalopathy (FSE) in domestic cats, and BSE in goats, to name a few. Therefore, the risk that this might occur with other prion diseases and cohabiting host species must not be neglected especially considering spontaneous cases of prion disease have been reported worldwide in humans, cattle, and small ruminants, and may exist in other species that have not been as extensively examined for prion diseases.

In some species, despite having been exposed to prions, no field cases of prion disease have ever been diagnosed. This may be for many reasons including: a low number of individuals examined, a short life span resulting in death from other causes before any prion disease can develop, culling at an early age or other circumstances. Reasons that might explain why species that have been experimentally proven susceptible to prion disease have never had naturally occurring cases reported. These include pigs, rabbits, mice, nonhuman primates, ferrets, and even horses where a transgenic mouse model with equine PrP was used.

Dogs are not included in this list for two reasons: experiment on dogs using prions is very limited (for various reasons, including ethical constraints) and no transgenic model has been generated. To date, no evidence exist that dogs can be infected naturally with prions, only theoretically using an in vitro assay that have, under extreme and specific conditions, succeeded in misfolding dog PrP<sup>C</sup>.

To complicate things further, prions can misfold into well differentiated conformations with specific pathobiological features, the prion strain phenomenon. Specific species are susceptible to a particular prion strain depending on the compatibility between the host PrP amino acidic sequence and the strain conformation of the infecting prion: for example, cats, despite having a PrP amino acidic sequence very similar to dogs, can be readily infected with BSE and CJD but only with great difficulty using CWD (incubation period over 3 years). So, when assessing susceptibility to prions of a given species not only is the host’s PrP sequence to be considered but also the prion strain. The theoretical susceptibility can be predicted by examining the misfolding capability of the chosen species’ PrP<sup>C</sup> in vitro by protein misfolding cyclic amplification (PMCA). Rabbits, a species with no reported field cases of transmissible spongiform encephalopathy (TSE) despite being sympatric with several prion susceptible ruminant species, were shown to have PrP<sup>C</sup> that was readily misfolded by BSE in vitro, and susceptibility to this prion strain was further corroborated by bioassay in transgenic mice with rabbit PRNP and experimentally in vivo. However, the scenario in horses, another putatively prion-resistant species, is somewhat different as horse PrP<sup>C</sup> can be misfolded, either in vitro by PMCA or by means of bioassay in mice expressing equine PrP<sup>C</sup> (TgEq) (albeit with low efficiency), but the resultant horse-adapted prions are unable to propagate disease in TgEq mice, even though their ability to infect the original species remains unaltered. This is interpreted as a nonadaptive prion amplification (NAPA) phenomenon.

We have demonstrated that wild-type (WT) dog PrP<sup>C</sup> (with an aspartic acid in position 163) could be misfolded by BSE prions in vitro by PMCA and the resultant prions were infectious in TgBov mice (over expressing bovine PrP<sup>C</sup>) but there is still no evidence in vivo of PrP<sup>res</sup> propagation in dogs. This resistance to prion disease makes canids, particularly the domestic dog (Canis lupus familiaris), an interesting species to study as, although having been exposed to BSE contaminated feed like cats, no definitive field case has ever been published despite a few unconfirmed reports.

Sequence alignment studies of the PRNP gene identified the presence of either glutamic (E) or aspartic (D) acids (both negatively charged amino acids) in position 163 in dogs PrP when compared to cats and these might be responsible for the differing resistance of the two species with respect to susceptibility to BSE and CWD. Furthermore, mouse PRNP with substitutions equivalent to the canine amino acid residues proved to be resistant to conversion to PrP<sup>res</sup> both in vitro, by means of recombinant PrP-based PMCA, and in vivo in two different transgenic mouse models with asparagine (N) to aspartic acid substitution at position 158 (N158D). Additionally, mouse PRNP with this canid substitution provided a protective dominant negative
effect by inhibiting PrP\textsuperscript{C} conversion in transgenic chimeras co-expressing WT mouse \textit{PRNP}.

The same substitution introduced into a bank vole PrP transgenic mouse model significantly delayed prion propagation in this highly prion susceptible model.\textsuperscript{34}

All members of the \textit{Canidae} family share a virtually identical \textit{PRNP} sequence with only a few polymorphic variants present. Among those, the presence of aspartic acid (D) and glutamic acid (E) in position 163 stands out as it is almost exclusive to this family\textsuperscript{35} which may be a possible evolutionary advantage as their diet is frequently based on ruminant meat.\textsuperscript{36,37}

In the present study, a transgenic mouse line has been generated bearing WT E163 dog \textit{PRNP} and challenged with a variety of prion isolates. To prove that the presence of a negatively charged amino acid at position 163 in canine PrP is critical in determining resistance to prion disease, one additional transgenic mouse line was generated expressing dog \textit{PRNP} but with asparagine 163 (D163N) as this residue at this position is present in most of the prion susceptible species. This model was then exposed to the same panel of isolates.

In this study, we confirm for the first time that dog PrP is unable to propagate any of the prion isolates we challenged them with definitively showing that canids are highly resistant to prion infection and that the resistance mechanism is encoded by the amino acid present at position 163 (D/E in canines vs N in the rest of prion susceptible species).

2 \quad MATERIALS AND METHODS

2.1 \quad Preparation of inocula for prion propagation studies

Brain homogenates (10\textsuperscript{-1} in phosphate buffered saline -PBS-) for use as seeds for PMCA or direct intracerebral inoculation were prepared manually using a glazed mortar and pestle from brains of animals clinically affected by various TSE: Classical BSE strain (BSE-C) and classical scrapie isolate, sheep scrapie brain pool 1 (SSBP/1) were supplied by Animal & Plant Heath Agency (UK), BSE-L field cases were supplied by Centro di Referenza Nazionale per le Encefalopatie Animali (Turin, Italy), CWD from the thalamus area of the brain of a female mule deer, genotype 225SS, infected with CWD (04-22412WSV2 EJW/GEJ), supplied by Department of Veterinary Sciences (University of Wyoming, Laramie, WY, USA), feline CWD from an experimental case of CWD infection in a domestic cat was supplied by Department of Microbiology, Immunology and Pathology, Colorado State University (Fort Collins, Colorado, USA),\textsuperscript{50} and Sheep-BSE was supplied by Ecole Nationale Vétérinaire (Toulouse, France). The atypical scrapie isolate was obtained from a field case diagnosed in the PRIOCAT laboratory, CRèSA-IRTA (Barcelona, Spain). BSE DoD163 PrPres was generated previously by PMCA using cattle BSE as the seed.\textsuperscript{22}

2.2 \quad Generation of in vitro PrPres by serial PMCA

The in vitro prion replication and PrPres detection of amplified samples was performed as described previously with minor modifications.\textsuperscript{51} Briefly, brains used for substrate were perfused using PBS + 5 mM EDTA and the blood-depleted brains were frozen immediately until required for preparing the 10% brain homogenates (PBS + NaCl 0.15 M + 1% Triton X-100). Brain homogenates (50-60 μL of 10%), either unseeded or seeded with the corresponding prion isolate/strain, were loaded into 0.2-mL of PCR tubes and placed into a sonication water bath at 37-38°C without shaking. Tubes were positioned on an adaptor placed on the plate holder of the sonicator (model S-700MPX, QSonica, Newtown, CT, USA) and subjected to incubation cycles for 30 minutes followed by a 20 seconds pulse of 150-220 watts sonication at 70-90% amplitude. Serial rounds of PMCA consisted of 24-48 hours of standard PMCA followed by serial in vitro 1:10 passages in fresh 10% brain homogenate substrate. An equivalent number of unseeded (four duplicates) tubes containing the corresponding brain substrate were subjected to the same number of rounds of PMCA in order to monitor for cross-contamination and/or the generation of spontaneous PrPres.

2.3 \quad Biochemical characterization of in vitro- and in vivo-generated prion strains

Protein misfolding cyclic amplification treated samples were incubated with 85-200 μg/mL of protease K (PK) for 1 hours at 42°C with shaking (450 rpm) as described previously.\textsuperscript{52} Digestion was stopped by adding electrophoresis Laemmli loading buffer and the samples were analyzed by Western blotting.

2.4 \quad Generation of \textit{TgDog E163} and \textit{TgDog D163N} mice

After isolation by PCR amplification from genomic DNA extracted using GeneJET Genomic DNA Purification Kit (Fermentas, Vilnius, Lithuania) from a E163 dog tissue sample using 5′ GGAGGTACATCATGTCGATTAAGCCCATATAGGCGAATG 3′ and 5′ GCCGGGGCGCCGGTTCAATCCACTATCAAGAATG 3′ as primers, the open reading frame (ORF) of the E163 dog \textit{PRNP} gene was cloned into the pGEM-T vector (Promega, Madison,
Wiscson, USA). In the same way, the ORF of D163 dog PRNP was isolated from the genomic DNA extracted from the tissue sample of a dog bearing D163 polymorphism using the same primers and cloned into pGEM-T vector. The dog E163-PrP ORF was excised from the cloning vector by using the restriction enzymes BsiWI (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) and FseI (New England Biolabs Ltd., Ipswich, Massachusetts, USA) and then inserted into a modified version of MoPrP.Xho vector as described previously, which was also digested with BstWI and FseI. This vector contains the murine PrP promoter and exon 1, intron-1, exon-2, and 3′ untranslated sequences. The genetic construct containing the dog D163N substitution was carried out by two-step PCR site-directed mutagenesis using pGEM dog D163 as template, using primers 5′ GAACATGTACCGCTACCCCAACAAATATACTA CGGG 3′ with 5′ GGCGCGGGCGCGCTCATCCCA CTATCAAGAGAATG 3′ and 5′ CCGTATGATACTT GTGTGGTTGACGGTACATGTTTC 3′ with 5′ GGCG GAAATTCATCATGTTGAAAGCCGGTACAGGTGGATAACC 3′ and 5′ ATGGCGAACCTTGGCTACTGGCGTCCACATAGG CG 3′. Then using the previous fragments as templates and primers 5′ GGCGGAATT CACATCATGTTGAAAGCCACATAGGCG 3′ and 5′ GGCGGGGGCGCGCTCATCCC ACTATCAAGAGAATG 3′, the dog D163N-PrP ORF was generated and cloned into the pGEM-T vector (Promega, Madison, Wisconsin, USA). It was also excised from the cloning vector using restriction enzymes BsiWI (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) and FseI (New England Biolabs Ltd., Ipswich, Massachusetts, USA), and then inserted into a modified version of MoPrP.Xho vector. Both transgenes were excised using NotI and purified with an Invisorb Spin DNA Extraction Kit (Invitek Molecular, Berlin, Germany) according to the manufacturer recommendations.

Transgenic mouse founders were generated by microinjection of DNA into pronuclei following standard procedures. DNA extracted from tail biopsies was analyzed by PCR using specific primers for the mouse exon 2 and 3′ untranslated sequences (5′ GAACTGAACCATTTCAACCGAG 3′ and 5′ CCGTATGATACTT GTGTGGTTGACGGTACATGTTTC 3′). Those which tested positive were bred to mice null for the mouse PRNP (PrP K.O. mice) in order to avoid endogenous expression of mouse prion protein. Absence of the mouse endogenous PRNP was assessed using the following primers: 5′ ATGGCGAACCTTGGCTACTGGGC 3′ and 5′ GATATGGGTAACCCCTCCTTGG 3′. The dog PrP expression levels of brain homogenates from transgenic mouse founders were determined by Western blot (WB) using anti-PrP monoclonal antibody (mAb) D18 and compared with the PrP expression levels from different dog brain homogenates.

The international code to identify these transgenic mouse lines are STOCK-Prnpmtm2Edin Tg(moPrpn dogPrP)14Bps and 129OLA-Prnpmtm2Edin-Tg(mPrpn-dogPrPD163N)1Sala although throughout the paper they are referred to as TgDog E163 and TgDog D163N mice, respectively.

2.5 | TgDog E163 and TgDog D163N mice inoculation

Mice of 42-56 days of age were intracerebrally inoculated under gaseous anesthesia (Isoflurane) through the right parietal bone. A 50 µL of SGC precision syringe was used with a 25 G gauge needle and coupled to a repeatability adaptor fixed at 20 µL. A dose of buprenorphine was subcutaneously injected before recovery to consciousness to reduce postinoculation pain. Mice were kept in a controlled environment at a room temperature of 22°C, 12 hours light-darkness cycle, and 60% relative humidity in HEPA filtered cages (both air inflow and extraction) in ventilated racks. The mice were fed ad libitum, observed daily and their clinical status assessed twice a week. The presence of 10 different TSE-associated clinical signs was scored. Positive TSE diagnosis relied principally on the detection of PrP(ES) (either by immunohistochemistry [IHC] and/or western blotting or ELISA) and associated spongiform changes on stained histological sections (see below) of the brain parenchyma.

2.6 | Ethics statement

All experiments involving TgDog animals were approved by the animal experimentation ethics committee of the Autonomous University of Barcelona (Reference number: 585-3487) in agreement with Article 28, sections (a), (b), (c), and (d) of the “Real Decreto 214/1997 de 30 de Julio” and the European Directive 86/609/CEE and the European Council Guidelines included in the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes.

All experiments involving TgDog D163N animals were approved by the Ethical Committee on Animal Welfare of the Laboratorio Central de Veterinaria (project code assigned by the Ethical Committee CEBA-07/2010) and also in agreement with the aforementioned European legislation and the Spanish Legislative Decree “Real Decreto 1201/2005 de 10 de Octubre.”

2.7 | Sample processing and general procedures

When the clinical end-point criteria were reached mice were euthanized by decapitation. The brain was extracted immediately and placed into 10% phosphate-buffered formalin. Transversal sections of the brain were performed at the levels
of the medulla oblongata, piriform cortex, and optic chiasm. Samples were embedded in paraffin-wax after dehydration through increasing alcohol concentrations and xylene. Four micrometer sections were mounted on glass microscope slides and stained with hematoxylin and eosin for morphological evaluation. Additional sections were mounted in 3-trietoxysilil-propilamine-coated glass microscope slides for IHC. The spinal cord and a partial section of the frontal cortex, including the olfactory bulbs, were separated prior to fixation and kept frozen for biochemical analysis.

2.8 | Immunohistochemistry

Immunohistochemistry for detection of PrP\textsuperscript{res} was performed as described previously.\textsuperscript{56} Briefly, deparaffinized sections were subjected to epitope unmasking treatments: immersed in formic acid and boiled at low pH (6.15) in a pressure cooker and pretreated with proteinase K. Endogenous peroxidases were blocked by immersion in a 3% of H\textsubscript{2}O\textsubscript{2} in methanol solution. Sections were then incubated overnight with anti-PrP MAb 6H4 primary antibody (1:2000, Prionics AG, Schlieren, Switzerland) or MAb Sha31 (1:1000, Bertin Pharma, Montigny le Bretonneux - France) and subsequently visualized using the DAKO Goat anti-mouse EnVision system (Ref. K400111/0, Agilent, Santa Clara, California, USA) and 3,3’-diaminobenzidine as the chromogen substrate. As a background control, incubation with the primary antibody was omitted.

3 | RESULTS

3.1 | Generation of TgDog E163: a model to evaluate canine susceptibility to prion infection

Once the effects of D/E at position 163 on mouse PRNP had been established\textsuperscript{32,33} the next logical experiment was to test the prion susceptibility in an in vivo model bearing WT canine PRNP. Considering obvious ethical and budgetary restrictions of using dogs as model, a transgenic mouse approach was pursued. Based on our previous experience, new mouse lines were generated by pronuclear injection of a construct consisting of the mouse PrP promoter and the E163 dog PRNP sequence. Six founders were obtained that transmitted the transgene to their progeny. After backcrossing to a line that did not express endogenous PrP (STOCK-Pnptm2Edin), expression levels of the transgene were analyzed by WB and one line was excluded because it expressed 10 times the levels of the endogenous gene and this could cause an undesired PrP\textsuperscript{C} over-expression associated phenotype.\textsuperscript{38,39} Four lines expressed less than two times the endogenous gene levels and were also excluded (additionally, two of those did not breed efficiently). Finally, only hemizygous line TgDog E163 (line 014) reproduced well and showed a consistent expression pattern of 2\times compared to the endogenous dog prion protein (PrP) level with an unaltered glycoform ratio upon Western blotting (Figure 1A). Moreover, the immunohistochemical labeling pattern of PrP\textsuperscript{C} was comparable to that of a WT mouse (Figure 1B). This line was selected for further studies.

3.2 | TgDog PrP\textsuperscript{C} in vitro and in vivo misfolding studies; none of the prion isolates resulted in misfolding

3.2.1 | TgDog E163 in vitro studies

An attempt was made to misfold dog PrP\textsuperscript{C} by PMCA using TgDog brain homogenates as substrates and using different prion strains as seeds. Ten rounds of serial PMCA were performed using four replicates for each seed including: cattle BSE-C, BSE-L, sheep-BSE, sheep scrapie, atypical scrapie, mule deer CWD, experimental feline CWD, and BSE dog(D163)-PrP\textsuperscript{res} (inoculum obtained in vitro by PMCA using dog (D163) brain homogenate as a substrate and cattle BSE as a seed).\textsuperscript{22} None of the isolates tested was able to misfold TgDog E163 PrP\textsuperscript{C} (Table 1).

3.2.2 | TgDog E163 bioassay

Even though in vitro results usually correlate well with bioassay, ultimately, infectivity can only be demonstrated by in vivo inoculation. The isolates used for inoculation were the ones described in the in vitro section above and negative control inocula were also included consisting of normal, non-infected brain homogenate (NBH) from cattle, dog, and sheep. None of the animals showed neurological clinical signs compatible with a TSE. Table 2 shows the number of animals inoculated for each isolate and a range of survival times post inoculation. Prion disease was ruled out in all the animals studied by means of Western blotting for detection of PrP\textsuperscript{res}, histopathology, and PrP\textsuperscript{res} IHC.

3.3 | Unsuccessful PMCA propagation of PrP\textsuperscript{res} from brains of inoculated TgDog E163

Even though no clinical signs nor PrP\textsuperscript{res} deposits were detected in any of the inoculated TgDog E163 mice by standard PrP\textsuperscript{res} detection methods [WB and IHC], PMCA was performed using perfused TgDog E163 brain homogenates as a substrate to determine if even a minute amount of PrP\textsuperscript{res} was present that could indicate otherwise undetected in vivo PrP misfolding. Pools of brains of TgDog mice inoculated for the bioassay study were prepared and used as seeds in the PMCA experiments. Six serial rounds of PMCA were performed...
to ensure the detection of minimal amounts of PrPSc and thereby rule out a putative propagation on a second in vivo passage. None of the pools showed detectable PrPSc after the six in vitro propagation rounds (Table 1).

3.4 | Generation of TgDog D163N mice: a model to determine the protective effect of aspartic acid at position 163 of the dog PrP

Since TgDog E163 mice were unable to propagate prions, as shown in previous studies with mouse and bank vole PrP, the amino acid that conferred apparent resistance, aspartic acid, was removed and substituted by asparagine at position 163 to determine if susceptibility to prions was recovered. New mouse lines were generated by pronuclear injection of a construct consisting of the mouse PrP promoter and the dog PrP sequence with the D163N substitution. From a total of five positive animals, four animal founders transmitted the transgene to their progeny. After backcrossing to a line that did not express endogenous PrP (STOCK-Prnptm2Edin), expression levels of the transgene were analyzed by Western blot. One line expressed less than 1× the WT dog PrP levels and was discarded, another line was discarded because it expressed 5× the dog PrP levels, and there was a risk of an overexpression phenotype. Of the two remaining lines, TgDog D163N (Line 483), expressing 2× the levels of dog PrP and with conserved glycoform ratio upon Western blotting, was chosen since this was the overexpression level obtained with the previous model (TgDog E163) (Figure 1A). Furthermore, immunohistochemical labeling of PrP was comparable to that found in WT (C57BL/6) brains, revealing a normal synaptic staining. Notice absence of labeling in the PrP-K.O. mouse brain. Samples were immunostained using Sha31 (1:1000) monoclonal antibody. Bar: 25 μm

3.5 | TgDog D163N mice are susceptible to classical BSE and sheep-BSE in vitro and in vivo

3.5.1 | In vitro studies

PMCA was performed using TgDog D163N mouse brain homogenates as a substrate. The same isolates as in previous sections were used as seeds and were subjected to 10 serial PMCA rounds with four replicates each. In contrast to
what happened with TgDog E163 brain homogenates, classical BSE and sheep-BSE were successfully propagated in this substrate (Table 1). This result suggests that the amino acid residue substitution D163N was responsible for the recovered susceptibility to PrPC misfolding.

### 3.5.2 TgDog D163N bioassay

Bioassays were conducted to ascertain if TgDog D163N mice were susceptible to prion infection in agreement with the in vitro results. The same panel of isolates mentioned above was used (Table 3). None of the inoculated mice developed TSE-associated clinical signs. However, upon euthanasia 6/11 mice inoculated with sheep-BSE showed evidences of infection as confirmed by Western blotting and/or immunohistochemistry (Figure 2). These data support the in vitro results that mutated dog PrP (D163N) is more susceptible to misfolding than WT dog PrP.

Spongiform change was mild and 5/10 animals presented PrPres deposits as evidenced by immunohistochemistry. The deposits were scant and consisted on a few plaque-like, small, round extracellular deposits (maximum 2) observed in the dorsal nuclei of the thalamus accompanied by scant fine punctate deposits in the surrounding neuropil (Figure 2B) in 4/5 animals. Also, in 2/5 animals, intracytoplasmic granular deposits in a few neurons of the brainstem (rostral nuclei of the medulla oblongata) were observed (Figure 2C).

### 3.6 In vitro amplification of potentially undetected PrPres in TgDog D163N mouse brains

In order to rule out that any of the other isolates inoculated in TgDog D163N had propagated in minute amounts undetectable by standard PrPres detection techniques but could be transmitted on a second passage, PMCA was performed using TgDog D163N mouse brain homogenates as substrate and pooled brains from each group of inoculated mice as seeds. Each pool was subjected to six rounds of serial PMCA providing PrPres detection sensitivity comparable to, if not greater than, a second passage in vivo.40 In this case, the sheep-BSE inoculated mice brain pool served as a positive control.

With the exception of sheep-BSE inoculated mice, no PrPres propagated in any of the remaining brain pools (Table 1 and Figure 3A). Serial PMCA was then repeated individually with the brains of mice inoculated with sheep-BSE in which no PrPres had been detected by WB or IHC. Of these animals, 10 out of 11 had PrPres present after in vitro amplification confirming the effectiveness of the PMCA procedure to reveal subclinical prion infections on first passage bioassay (Figure 3B). Homogenates from the
mouse brains inoculated with cattle BSE were also tested individually by serial PMCA and all of them failed to propagate PrPres (Figure 3B) confirming the high specificity of the method.

### 3.7 Attempting to overcome the barrier: from TgDog D163N PrP\textsuperscript{PrPres} to TgDog E163

We wanted to determine whether, once misfolded by sheep-BSE, the new adapted dog D163N sheep-BSE would be capable of misfolding WT dog PrP\textsuperscript{C}. TgDog E163 mouse brain homogenates and two different dog brain homogenates coming from different breeds were used as PMCA substrates (English Cocker Spaniel and German Wirehaired Pointer). Five rounds of serial PMCA were performed and, neither TgDog E163 brain homogenate nor actual dog brain homogenates were able to propagate the adapted dog D163N sheep-BSE. This result further confirms the reluctance of dog PrP\textsuperscript{C} to misfold and the critical role of the amino acid at position 163 (Figure 4A).

In order to demonstrate that TgDog D163N-adapted sheep-BSE retained its propagation capacity in its original host PrP\textsuperscript{C}, cattle brain homogenate was used as a substrate on five serial rounds of PMCA. As expected, cattle PrP\textsuperscript{C} could easily propagate the TgDog D163N-adapted sheep-BSE seed, resulting in PrP\textsuperscript{PrPres} with the conserved predominantly diglycosylated band characteristic of this prion strain (Figure 4B).

### 4 Discussion

Considerable amounts of data have been generated suggesting that canine PrP\textsuperscript{C} is highly resistant to conformation change to PrP\textsuperscript{PrPres} compared to prion susceptible species.\textsuperscript{32,32,36,37,41,42} Our group has now established, both in vivo and in vitro, that the amino acid residue in position 163...
is the key determinant and that an aspartic or a glutamic acid in this position (or equivalent in other species) is what conferred resistance to prion infection in the models in which those proteins were expressed. Furthermore, these PrP\textsuperscript{C} that are highly resistant to conformation change showed a dominant negative effect when co-expressed with WT mouse PrP. Prior to the present report, evidence confirming that murine models expressing WT canine PrP\textsuperscript{C} were resistant to infection by a panel of prion isolates from different species was lacking and we have addressed this by both bioassays and in vitro propagation experiments.

Our conclusions rely on the absence of clinical disease in a single passage in TgDog E163. However, when a transmission/species barrier is present, minute amounts of PrP\textsuperscript{C} can be
formed on first passage in the absence of any clinical disease or neuropathological lesions at the end of the life span of the mouse model. To investigate this phenomenon all challenged animals were not euthanized until the end of their life span (or in some cases due to, mostly, age-related intercurrent disease). Further passages in the same mouse model might have disclosed this but, since these experiments are lacking, in order to ensure the detection of minimal amounts of PrP\textsuperscript{res}, pools of inoculated TgDog mice brains were subjected to serial PMCA rounds using TgDog brain homogenates as a substrate. This technique has been demonstrated to propagate minute amounts of PrP\textsuperscript{res}.40 In all instances no PrP\textsuperscript{res} was present (Table 1) confirming the results obtained in the bioassay.

The total absence of prion infection or in vitro propagation with any of the prions used to challenge TgDog could be attributed to reasons other than the extreme resistance of canine PrP\textsuperscript{C} to misfolding such as inherent issues with the generation of the transgenic models that may prevent infection. WB analysis of the PrP\textsuperscript{C} showed identical migration and glycosylation pattern to WT dog PrP\textsuperscript{C} indicating correct
posttranslational modifications (Figure 1A). Additionally, the immunohistochemical localization indicated the correct anatomical expression of the protein on the neuronal cell membrane (Figure 1B), thus confirming the role of dog PrP amino acid sequence in preventing prion infection.

The only report unequivocally demonstrating that dog PrP^C^ can be misfolded was achieved only in vitro, under highly favorable conditions, by a single prion strain and using dog brain homogenate expressing the 163D polymorphism. However, this TgDog model was made prior to understanding the importance of the amino acid residue in position 163. Therefore, in the current work 163E was chosen, as this is exclusive to domestic dogs although both D and E can occur in this position. The 163D polymorphism is present in other canidae species and also in some members of the closely related mustelidae family (wolverine and pine marten, members of the marinae subfamily). Differences in behavior between 163E and 163D containing dog PrP were explored by cell-based in vitro studies and in silico analysis of the area containing residue 163 and these revealed differences in the side chain lengths of each residue, the effects of which are unknown. Since the mechanism of action that makes dog PrP^C^ particularly resistant to misfolding might be related to the specific surface charge distribution conferred by these negatively charged amino acids and/or steric hindrance, it is not surprising that the slight differences between the side chains of E and D resulted in small differences in the misfolding capacity of each PrP^C^. The dog prion from the aforementioned study, formed in vitro by seeding with BSE (BSE-Dog D163 PrPres), was unable to propagate when inoculated intracerebrally in our TgDog model indicating that E163 poses a greater limitation for misfolding than D163. However, the BSE-Dog D163 PrPres isolate was propagated efficiently in a TgBov model (BoTg110) suggesting prion
amplification without adaptation to the new host but conserving its pathobiological features toward a host with the original cattle PrP\textsuperscript{C}, similar to that described previously for other isolate-host combination such as scrapie in TgHorse mice.\textsuperscript{21}

The possible relevance of the negatively charged amino acid residue in position 163 of dog PrP to their resistance to prion infection was initially suspected from sequence alignment studies of the PRNP of several members of the canidae family with those of susceptible species. These studies revealed that feline PrP was the most similar in terms of amino acid sequence and as domestic cats are susceptible to at least three known prion strains (BSE, CWD, and CJD)\textsuperscript{26,44-46} the six amino acid difference between canine and feline PrP was studied in detail. The E/D polymorphism in position 163 was highlighted due to its almost exclusive presence in the canidae family and chosen as the most likely candidate for canine resistance to prion disease.\textsuperscript{32} NMR assessment of dog’s PrP\textsuperscript{C} structure also pointed out the unique charge distribution posed by the presence of D in position 163.\textsuperscript{47} Furthermore, experiments with transgenic Drosophila expressing the D159N mutation (human equivalent of dogs 163) showed toxicity in contrast to WT dog PrP, concluding that D in position 159 was protective.\textsuperscript{48} Our results with TgDog, together with previous reports on canine resistance to prion infection\textsuperscript{32-34} clearly identify residue 163 as the strongest effector of the resistance of canine PrP\textsuperscript{C} to misfolding. Therefore, to definitively demonstrate the importance of E or D in position 163, we substituted into the dog PrP the most conserved residue in susceptible species, asparagine, to determine if susceptibility of canine protein to misfolding could be induced. In an experiment conceptually opposite to the one previously conducted with mouse PrP, which was rendered resistant to prion infection by substituting asparagine for aspartic acid at the equivalent position 158,\textsuperscript{32} the D163N substitution was performed in dog PrP. This eliminates the negative charge and/or steric hindrance that aspartic acid might confer on that region of dog PrP\textsuperscript{C}. The resultant transgenic mice could be infected with sheep-BSE inocula. These animals did not show disease associated clinical signs but were confirmed as TSE positives by IHC and PMCA, thus, it cannot be ruled out that very mild clinical signs might have been masked by age-related changes. Additionally, in vitro amplification using brain homogenates of this TgDog D163N model as substrate allowed misfolding of D163N canine PrP\textsuperscript{C} using either sheep-BSE or cattle BSE as seeds. This result strongly supports that amino acid 163 in dog PrP is the main determinant of its resistance to misfolding by prions. However, since susceptibility was not recovered to all the challenged prion isolates, including classical and atypical scrapie, BSE-L, mule deer CWD, and cat CWD (Table 1), this amino acidic position cannot be regarded as the sole resistance determinant. The prion transmission barrier is assumed to be determined by various factors, including the host PrP sequence and the structure (strain) of the prion. A particular strain will also display a different behavior depending on its own PrP sequence. A clear example of this is BSE, which is more virulent in a sheep PrP environment than in bovine PrP\textsuperscript{C} this could be the explanation as to why this particular strain was the one capable of misfolding TgDog D163N PrP\textsuperscript{C} as opposed to the other isolates. Also, the more similar the PrP sequence is between the host and the inoculated isolate, the lower the transmission barrier should be.

In this regard, it is surprising that the cat-adapted CWD isolate, despite having an amino acid sequence with only a five residues difference from dog D163N PrP (residues 99, 107, 116, 180, and 188 in dog PrP numbering, some of them identical to the amino acids found in other susceptible species), could not be propagated in TgDog D163N substrate which suggest a relevant role of these amino acids in the resistance of this species. It also cannot be excluded that a 2x overexpression of PrP\textsuperscript{C} is not high enough to overcome the transmission barrier or that specific strain features make CWD less capable of misfolding TgDog D163N PrP\textsuperscript{C} than sheepBSE.

Interestingly, even sheep-BSE misfolded TgDog D163N could not misfold WT dog PrP\textsuperscript{C} (using TgDog 163E brain homogenate as a substrate) in our in vitro experiments despite only a single amino acid difference. Again, this suggests a critical role of negatively charged residues at position 163 on PrP misfolding.

In summary, this study provides further experimental evidence that canids, particularly domestic dogs, are the most prion resistant species studied to date and that position 163 in dog PrP is key in conferring resistance to misfolding thereby establishing this amino acid position coupled with negatively charged residues as a clear therapeutic target for prion diseases.

ACKNOWLEDGMENTS
The authors would like to thank the following for their support: Ikerbasque foundation, vivarium, and maintenance from CIC bioGUNE and Patricia Piñeiro for technical support. Sierra Espinar, Marta Valle, and Mariano Moreno for technical support, and IRTA-CReSA’s bioccontainment unit staff for care and maintenance of the animals. Olivier Andréoletti, Jean Jewell, and Fabrizio Tagliavini for the sheep-BSE, CWD, and BSE-L brain tissue samples, respectively. Glenn Telling and Jifeng Bian for the plasmid phgPrP-MCS. Dr. Mark P. Dagleish (Moredun Research Institute) for useful discussion and advice. This work was supported financially by two Spanish grants, (AGL2015-65046-C2-1-R (JC) and AGL2008-05296-C02 (EV and BP)) (MINECO/FEDER), and Interreg (POCTEFA EFA148/16) grant. We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644). IRTA is supported by CERCA Programme/Generalitat de Catalunya.

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
AUTHOR CONTRIBUTIONS
E. Vidal, N. Fernández-Borges, M. Pumarola, and J. Castilla designed research; E. Vidal, N. Fernández-Borges, H. Erañá, B. Parra, J.M. Charco, M. Ordoñez, M.A. Pérez-Castro, T. Mayoral performed research; B. Pintado, M.A. Sánchez-Martín, and C.K. Mathiason contributed new research tools, the transgenic mouse models; E. Vidal, N. Fernández-Borges, M. Pumarola, T. Mayoral, and J. Castilla analyzed the data; and E. Vidal, N. Fernández-Borges, H. Erañá, and J. Castilla wrote the paper.

REFERENCES
1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science*. 1982;216:136-144.
2. Sigurdson CJ, Miller MW. Other animal prion diseases. *Br Med Bull*. 2003;66:199-212.
3. Windl O, Dawson M. Animal prion diseases. *Subcell Biochem*. 2012;65:497-516.
4. Benestad SL, Mitchell G, Simmons M, Ytrehus B, Vikøren T. First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer. *Vet Res*. 2016;47:88.
5. EFSA (European Food Safety Authority). The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSE) in 2016. *EFSA J*. 2017;15:1-68.
6. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that “new variant” CJD is caused by the BSE agent. *Nature*. 1997;389:498-501.
7. Wyatt JM, Pearson GR, Smerdon TN, Gruffydd-Jones TJ, Wells GA, Wilesmith JW. Naturally occurring scrapie-like spongiform encephalopathy in five domestic cats. *Vet Rec*. 1991;129:233-236.
8. Eloït M, Adjou K, Coulpier M, et al. BSE agent signatures in a goat. *Vet Rec*. 2005;156:523-524.
9. Puoti G, Bizz I, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. *Lancet Neurol*. 2012;11:618-628.
10. Baron T, Biacabe AG, Arsac JB, Benestad S, Groschup MH. Atypical transmissible spongiform encephalopathies (TSEs) in runnants. *Vaccine*. 2007;25(30):5625-5630.
11. Benestad SL, Arsac JM, Goldmann W, Noremark M. Atypical/ Nor98 scrapie: properties of the agent, genetics, and epidemiology. *Vet Res*. 2008;39:19.
12. Hedman C, Bolea R, Marín B, et al. Transmission of sheep-bovine spongiform encephalopathy to pigs. *Vet Res*. 2016;47:14.
13. Castilla J, Gutiérrez-Adán A, Brun A, et al. Subclinical bovine spongiform encephalopathy in transgenic mice expressing porcine prion protein. *J Neurosci*. 2004;24:5063-5069.
14. Torres JM, Espinosa JC, Aguilar-Calvo P, et al. Elements modulating the prion species barrier and its passage consequences. *PLoS ONE*. 2014;9(3):e89722.
15. Espinosa JC, Herva ME, Andréoletti O, et al. Transgenic mice expressing porcine prion protein resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie. *Emerg Infect Dis*. 2009;15:1214-1221.
16. Chianini F, Fernández-Borges N, Vidal E, et al. Rabbits are not resistant to prion infection. *Proc Natl Acad Sci USA*. 2012;109:5080-5085.
17. Piccardo P, Cervenak J, Yakovleva O, et al. Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology. *J Comp Pathol*. 2012;147:84-93.
18. Marsh RF, Kincaid AE, Bessen RA, Bartz JC. Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). *J Virol*. 2005;79:13794-13796.
19. Greenwood AD, Vincendeau M, Schmädlieke AC, Montag J, Seifarth W, Motzkuus D. Bovine spongiform encephalopathy infects endogenous retrovirus expression in distinct brain regions of cynomolgus macaques (Macaca fascicularis). *Mol Neurodegener*. 2011;6:44.
20. Sigurdson CJ, Mathiason CK, Perrott MR, et al. Experimental chronic wasting disease (CWD) in the ferret. *J Comp Pathol*. 2008;138:189-196.
21. Bian J, Khaychuk V, Angers RC, et al. Prion replication without host adaptation during interspecies transmissions. *Proc Natl Acad Sci USA*. 2017;114:1141-1146.
22. Vidal E, Fernández-Borges N, Pintado B, et al. Bovine spongiform encephalopathy induces misfolding of alleged prion-resistant species cellular prion protein without altering its pathobiological features. *J Neurosci*. 2013;33:7778-7786.
23. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. *Science*. 2007;318:930-936.
24. Fraser H, Pearson GR, McConnell I, Bruce ME, Wyatt JM, Gruffydd-Jones TJ. Transmission of feline spongiform encephalopathy to mice. *Vet Rec*. 1994;134:449.
25. Gourmelon P, Amyx HL, Baron H, Lemercier G, Court L, Gibbs CJ. Sleep abnormalities with REM disorder in experimental Creuzfeldt-Jakob disease in cats: a new pathological feature. *Brain Res*. 1987;411:391-396.
26. Mathiason CK, Nalls AV, Seelig DM, et al. Susceptibility of domestic cats to chronic wasting disease. *J Virol*. 2013;87:1947-1956.
27. Fernández-Borges N, Chianini F, Erañá H, et al. Naturally prion resistant mammals: a utopia? *Prion*. 2012;6:425-429.
28. Vidal E, Fernández-Borges N, Pintado B, et al. Transgenic mouse bioassay: evidence that rabbits are susceptible to a variety of prion isolates. *PLOS Pathog*. 2015;11:e1004977.
29. Castilla J, Gutiérrez-Adán A, Brun A, et al. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. *Arch Virol*. 2003;148:677-691.
30. David M, Tayebi M. OR-09: canine spongiform encephalopathy—a new form of animal prion disease. Amsterdam, The Nederlands: PRION 2012; 2012.
31. Kortz GD, Meier WA, Higgins RJ, et al. Neuronal vacuolation and spinocerebellar degeneration in young Rottweiler dogs. *Brain Pathol*. 2015;25:44.
32. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. *Science*. 2007;318:930-936.
33. Sigurdson CJ, Mathiason CK, Perrott MR, et al. Experimental chronic wasting disease (CWD) in the ferret. *J Comp Pathol*. 2008;138:189-196.
34. Otero A, Hedman C, Fernández-Borges N, et al. Unraveling the key to the resistance of canids to prion diseases, delays propagation of two prion strains in highly susceptible transgenic mouse models. *Mol Neurobiol*. 2019;55:6182-6192.
35. Stewart P, Campbell L, Skogtvedt S, et al. Genetic predictions of prion disease susceptibility in carnivore species based on variability of the prion gene coding region. *PLoS ONE*. 2012;7:e50623.

36. Fernández-Borges N, Eraña H, Castilla J. Behind the potential evolution towards prion resistant species. *Prion*. 2018;2018:1-5.

37. Stewart P, Campbell L, Skogvedt S, et al. Genetic predictions of prion disease susceptibility in carnivore species based on variability of the prion gene coding region. *PLoS One*. 2012;7(12):e50623.

38. Castilla J, Gutierrez-Adan A, Brun A, et al. Transgenic mice expressing bovine PrP with a four extra repeat octapeptide insert mutation show a spontaneous, non-transmissible, neurodegenerative disease and an expedited course of BSE infection. *FEBS Lett*. 2005;579:6237-6246.

39. Westaway D, DeArmond SJ, Cayetano-Canlas J, et al. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. *Cell*. 1994;76:117-129.

40. Saa P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. *J Biol Chem*. 2006;281:35245-35252.

41. Vidal E, Fernández-Borges N, Pintado B, et al. Exploring the risks of a putative transmission of BSE to new species. *Prion*. 2013;7:443-446.

42. Sanchez-Garcia J, Jensen K, Zhang Y, Rincon-Limás DE, Fernandez-Funez P. A single amino acid (Asp159) from the dog prion protein suppresses the toxicity of the mouse prion protein in Drosophila. *Neurobiol Dis*. 2016;95:204-209.

43. Castilla J, Gutierrez Adan A, Brun A, et al. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. *Arch Virol*. 2003;148:677-691.

44. Aldhous P. Spongiform encephalopathy found in cat. *Nature*. 1990;345:194.

45. Wyatt JM, Pearson GR, Smerdon TN, Gruffydd-Jones TJ, Wells GA, Wilesmith JW. Naturally occurring scrapie-like spongiform encephalopathy in five domestic cats. *Vet Rec*. 1991;129:233-236.

46. Zanusso G, Nardelli E, Rosati A, et al. Simultaneous occurrence of spongiform encephalopathy in a man and his cat in Italy. *Lancet*. 1998;352:1116-1117.

47. Lysek DA, Schorn C, Nivon LG, et al. Prion protein NMR structures of cats, dogs, pigs, and sheep. *Proc Natl Acad Sci USA*. 2005;102:640-645.

48. Sanchez-Garcia J, Fernandez-Funez P, D159 and S167 are protective residues in the prion protein from dog and horse, two prion-resistant animals. *Neurobiol Dis*. 2018;119:1-12.

49. Padilla D, Béringue V, Espinosa JC, et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. *PLoS Pathog*. 2011;7:e1001319.

50. Mathiason CK, Nalls AV, Seelig DM, et al. Susceptibility of domestic cats to chronic wasting disease. *J Virol*. 2013;87:1947-1956.

51. Fernández-Borges N, Di Bari MA, Eraña H, et al. Cofactors influence the biological properties of infectious recombinant prions. *Acta Neuropathol*. 2018;135:179-199.

52. Eraña H, Fernández-Borges N, Elezgarai SR, et al. In vitro approach to identify key amino acids in low susceptibility of rabbit prion protein to Misfolding. *J Virol*. 2017;91(24):e01543-17.

53. Borchelt DR, Davis J, Fischer M, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. *Genet Anal*. 1996;13:159-163.

54. Leclerc E, Peretz D, Ball H, et al. Conformation of PrPC on the cell surface as probed by antibodies. *J Mol Biol*. 2003;326:475-483.

55. Scott M, Foster D, Mirenda C, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. *Cell*. 1989;59:847-857.

56. Siso S, Ordoñez M, Cordón I, Vidal E, Pumarola M. Distribution of PrPres in the brains of BSE-affected cows detected by active surveillance in Catalonia, Spain. *Vet Rec*. 2004;155:524-525.

How to cite this article: Vidal E, Fernández-Borges N, Eraña H, et al. Dogs are resistant to prion infection, due to the presence of aspartic or glutamic acid at position 163 of their prion protein. *The FASEB Journal*. 2020;34:3969–3982. [https://doi.org/10.1096/fj.201902646R](https://doi.org/10.1096/fj.201902646R)